SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-047259
Filing Date
2021-09-08
Accepted
2021-09-08 08:37:40
Documents
68
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cadl-10q_20210630.htm   iXBRL 10-Q 2915221
2 EX-31.1 cadl-ex311_6.htm EX-31.1 18828
3 EX-31.2 cadl-ex312_7.htm EX-31.2 18575
4 EX-32.1 cadl-ex321_8.htm EX-32.1 8387
5 EX-32.2 cadl-ex322_9.htm EX-32.2 8622
  Complete submission text file 0001564590-21-047259.txt   7873678

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cadl-20210630.xsd EX-101.SCH 47326
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE cadl-20210630_cal.xml EX-101.CAL 33368
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cadl-20210630_def.xml EX-101.DEF 178167
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20210630_lab.xml EX-101.LAB 354999
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20210630_pre.xml EX-101.PRE 294416
11 EXTRACTED XBRL INSTANCE DOCUMENT cadl-10q_20210630_htm.xml XML 1105839
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40629 | Film No.: 211240814
SIC: 2836 Biological Products, (No Diagnostic Substances)